Zachary Bessette

GU Oncology Now

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental new drug application for Merck&rsquo;s WELIREG (belzutifan) in patients who were previously treated for advanced renal cell carcinoma (RCC).The acceptance of this priority review is based on results from the phase 3 <a href="https://guoncologynow.com/post/litespark-005-belzutifan-improves-pfs-in-previously-treated-patients-with-advanced-rcc" target="_blank" rel="noopener">LITESPARK-005</a> trial, which were read out in August and showed a statistically significant and clinically meaningful improvement in progression-free survival compared with everolimus in patients with advanced RCC who experienced disease progression after PD-1/PD-L1 and VEGF-TKI therapies.A statistically significant improvement in objective response rate, the trial&rsquo;s key secondary end point, was also reported.&ldquo;Patients with advanced RCC whose cancer progresses following immune checkpoint and anti-angiogenic therapies face a poorer prognosis, and for those patients, there is a crucial unmet need for new options with an alternative mechanism of action,&rdquo; said Marjorie Green, MD, senior vice president and head of late-stage oncology, global clinical development, at Merck, in a <a href="https://finance.yahoo.com/news/fda-accepts-priority-review-merck-104500513.html" target="_blank" rel="noopener">press release</a>. &ldquo;The FDA&rsquo;s priority review designation of this application reinforces the urgency to provide new options to previously treated patients with advanced RCC.&rdquo;Belzutifan was the first HIF-2&alpha; inhibitor approved in the United States. It is currently indicated for patients with von Hippel-Lindau disease who require therapy for associated RCC, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors.The HIF-2&alpha; inhibitor is being further assessed in LITESPARK-011 and LITESPARK-012 as a second-line therapy for treatment-na&iuml;ve advanced disease, and in LITESPARK-022 as an adjuvant therapy option.

FDA Grants Priority Review to Belzutifan in Previously Treated Advanced RCC

Advanced Renal Cell Carcinoma

The US FDA has accepted for priority review the supplemental new drug application for belzutifan in patients who were previously treated for advanced RCC.

FDA Grants Priority Review to Belzutifan in Advanced RCC

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe